58. 肥大型心筋症 [臨床試験数:92,薬物数:126(DrugBank:35),標的遺伝子数:40,標的パスウェイ数:141

Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-002242-17-GB30/07/202003/06/2020A trial of trientine in patients with hypertrophic cardiomyopathyA randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy. - TEMPEST Hypertrophic Cardiomyopathy (HCM)
MedDRA version: 20.0Level: PTClassification code 10020871Term: Hypertrophic cardiomyopathySystem Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Cufence
Product Name: Cufence
INN or Proposed INN: Trientine
Other descriptive name: Triethylinetetramine dihydrochloride
Product Name: Placebo
Manchester University NHS Foundation TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
172Phase 2United Kingdom